xc130-a10h
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 11, 2019 (NCT04043338)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- Dopamine D2 receptorPARTIAL AGONIST
DRD2 partial agonist
- Serotonin 2b (5-HT2b) receptorANTAGONIST
HTR2B antagonist
- Serotonin 1b (5-HT1b) receptorANTAGONIST
HTR1B antagonist
- Sigma opioid receptorANTAGONIST
SIGMAR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04043338 | Phase 1 | Aug 11, 2019 | Celerion, Xoc Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celerion | For profit | 1 | 0 | 1 | 2019 |
| Xoc Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1